K. C. Ensrud

Learn More
To examine the risk of mortality following all clinical fractures, we followed 6459 women age 55–81 years participating in the Fracture Intervention Trial for an average of 3.8 years. All fractures and deaths were confirmed by medical record or death certificate. Clinical fractures were fractures that came to medical attention. Fracture status was used as a(More)
To determine the ability of bone density to predict fractures in very elderly women, we examined the association of bone density with non-spine, hip, wrist and humerus fractures in 8699 Caucasian women aged 65–79 years and 1005 women aged 80 years and older who were participants in the prospective Study of Osteoporotic Fractures. Follow-up averaged 4.9(More)
In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1–84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1–84) compared to alendronate. No baseline participant characteristic consistently predicted increased bone density response to PTH(1–84), although women with larger changes in 1,25(More)
  • 1